Company Profile

Sanguine Biosciences Inc
Profile last edited on: 9/12/19      CAGE: 7EQX5      UEI: K2BANCKDAJJ9

Business Identifier: Enabling conduct of clinical trials through at-home-of =patient resources and tools
Year Founded
2010
First Award
2019
Latest Award
2019
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5000 Van Nuys Boulevard Suite 205
Sherman Oaks, CA 91423
   (855) 836-4759
   info@sanguinebio.com
   www.sanguinebio.com
Location: Single
Congr. District: 30
County: Los Angeles

Public Profile

Sanguine BioSciences is a biotechnology company structured to address bridging the gap between patients and researchers developing personalized medicine. Directly challanging the tradition model for clinical trials, the Sanguie approach is to bring those clinical trials into the home. From the premise that it should be easy for patients to contribute to the advancement of research for medical conditions that matter most to them, regardless of their location or ability to travel by bringing health care professionals to the home, the firm's proprietary platform seamlessly integrates information from site/sponsor, mobile clinical staff, and patients, increasing efficiency, consistency, and quality for each at-home visit. The firm's mobile staff cover the US, Canada and Europe. With each staffer trained on specific protocols and carrying the credentials that are necessary in conducting clinical trial procedures at the patient's home, the effort is to widen patient reach for improved recruitment, decrease patient burden for improved retention, and decrease site-work effort.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 1 NSF $224,981
Project Title: Advanced Direct-To-Patient Data Aggregation Platform for Clinical Trial Recruitment.

Key People / Management

  Brian Neman -- CEO & Co-Founder

  Chelsea Bouvier

  Ivan Ivankovich -- CFO

  Gerald Lee -- Chief Product Officer

  Amanda Leong

  Scott O'Donnell

Company News

There are no news available.